首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   57篇
  免费   7篇
  国内免费   2篇
妇产科学   1篇
基础医学   9篇
临床医学   2篇
内科学   9篇
神经病学   1篇
外科学   1篇
综合类   3篇
药学   6篇
肿瘤学   34篇
  2023年   1篇
  2022年   2篇
  2021年   4篇
  2020年   3篇
  2019年   2篇
  2018年   6篇
  2017年   4篇
  2016年   3篇
  2015年   8篇
  2014年   10篇
  2013年   4篇
  2012年   3篇
  2011年   2篇
  2010年   1篇
  2009年   1篇
  2007年   2篇
  2006年   1篇
  2004年   1篇
  2000年   2篇
  1999年   1篇
  1998年   3篇
  1997年   1篇
  1993年   1篇
排序方式: 共有66条查询结果,搜索用时 187 毫秒
31.
32.
目的:分析并评价10种外周血细胞游离核酸标志物在胃癌诊断中的应用价值。方法:提取胃癌患者及健康对照者的血清总RNA,反转录后采用实时荧光聚合酶链反应对候选基因进行检测,同时采用电化学发光免疫分析法检测癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、CA724,并运用Logistic回归及受试者工作特征(ROC)曲线对标志物进行分析。结果:胃癌患者血清中TP73(DNp73α)及肝细胞生长因子受体c-MET表达量较健康对照者显著增高(P<0.05)。c-MET检测对胃癌诊断的灵敏度为65.5%,特异度为76.4%,曲线下面积(AUC)为0.73,与TP73(DNp73α)比较,两者间的AUC差异有统计学意义(P<0.05)。c-MET与CEA、CA199、CA724联合检测时,其诊断灵敏度为75.0%,特异度为87.3%,AUC为0.83;与仅CEA、CA199、CA724三者联合检测相比,AUC差异有统计学意义(P<0.05)。不同肿瘤转移情况、不同TNM分期的患者,其c-MET表达量明显不同(P<0.05)。结论:检测外周血c-MET表达在胃癌诊断中具有一定价值,可作为临床常用胃癌肿瘤标志物的补充。  相似文献   
33.
目的 探讨肝细胞生长因子(HGF)、肝细胞生长因子受体(c-MET)及血管内皮生长因子(VEGF)的表达与非小细胞肺癌临床病理的关系.方法 将组织标本分为原发灶组(357例)和正常对照组(68例),分别采用免疫组织化学方法检测各组标本中HGF、c-MET及VEGF的表达情况.结果 非小细胞肺癌原发灶组织和正常组织中HGF表达阳性率分别为51.26% (183/357)和10.29% (7/68),两组之间差异有统计学意义(P<0.05);非小细胞肺癌原发灶组织和正常组织中c-MET表达阳性率分别为60.22% (215/357)和14.71%(10/68),两组间差异有统计学意义(P<0.05);非小细胞肺癌原发灶组织和正常组织中VEGF表达阳性率分别为45.38%(162/357)和11.76%(8/68),两组间差异有统计学意义(P<0.05);HGF阳性表达率与肿瘤组织分化程度及临床分期无关(P>0.05),c-MET及VEGF阳性表达率与肿瘤组织分化程度及临床分期相关(P<0.05).结论 HGF和c-MET、VEGF可能共同参与了非小细胞肺癌的发生和发展,c-MET和VEGF或可作为预测非小细胞肺癌患者预后的标记物.  相似文献   
34.

Objective

Tyrosine-protein kinase MET (c-MET) has been reported to be a prognostic marker and suitable therapeutic target for ovarian cancer. BMS-777607, a small molecule, can inhibit MET and other protein kinase activities. The present study was conducted to investigate the mechanism of action and antitumor effect of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.

Materials and methods

Ovarian cancer cells with constitutively activated c-MET were first identified through Western blot analysis. Bio-behaviors, including signal transduction, proliferation, apoptosis, and migration, of the cells with constitutively activated c-MET were evaluated after BMS-777607 treatment. Liu's stain and immunological staining of α-tubuline were performed to evaluate the ploidy of the cells. A xenograft mouse model was also used to evaluate the antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.

Results

BMS-777607 could induce the highest inhibition of cell growth in ovarian cancer cells constitutively expressing c-MET. Treating SKOV3 cells with BMS-777607 could reduce c-MET activation and inhibit downstream cell signaling, thus causing cell apoptosis and polyploidy as well as cell cycle and cell migration inhibition. This molecule also inhibited tumor growth in a mouse xenograft model of SKOV3 ovarian cancer cells in vivo.

Conclusion

BMS-777607 exhibits antitumor effects on ovarian cancer cells that constitutively express c-MET through c-MET signaling blockade and the inhibition of Aurora B activity. Combination treatments to enhance the effects of BMS-777607 warrant investigation in the future.  相似文献   
35.
Hepatocyte growth factor/scatter factor-induced intracellular signalling   总被引:4,自引:0,他引:4  
Hepatocyte growth factor (HGF) identical to scatter factor (SF) is a glycoprotein involved in the development of a number of cellular phenotypes, including proliferation, mitogenesis, formation of branching tubules and, in the case of tumour cells, invasion and metastasis. This fascinating cytokine transduces its activities via its receptor encoded by the c-met oncogene, coupled to a number of transducers integrating the HGF/SF signal to the cytosol and the nucleus. The downstream transducers coupled to HGF/MET, most of which participate in overlapping pathways, determine the development of the cell's phenotype, which in most cell types is dual.  相似文献   
36.

Introduction

Increased mesenchymal-epithelial transition factor gene (c-MET) expression in several human malignancies is related to increased tumor progression and is a new potential drug target for several types of cancers. In the present study, we investigated the incidence of c-MET overexpression and its prognostic significance in patients with colorectal cancer (CRC).

Patients and Methods

We retrospectively reviewed the data from 255 stage IV CRC patients who had results from a c-MET immunohistochemical test at Samsung Medical Center. We explored the relationships between c-MET overexpression and clinicopathological features and survival.

Results

Primary tumor sites were 67 right-sided colon, 98 left-sided colon, and 90 rectum. Forty-two patients (16.7%) had poorly differentiated or mucinous carcinoma. Among the 255 patients, 39 (15.3%) exhibited c-MET overexpression. There was no significant difference in the prevalence of c-MET overexpression according to primary site, histologic differentiation, molecular markers, or metastatic sites. In a comparison of the tumor response to first-line chemotherapy according to the level of c-MET expression, we found no significant difference in either partial response or disease control rate. In the survival analysis, patients with c-MET overexpression had significantly shorter overall survival (39 vs. 27 months; P = .018) and progression-free survival (PFS) during bevacizumab treatment (10 vs. 7 months; P = .024).

Conclusion

c-MET overexpression, which was detected in 39 CRC patients (15.3%) irrespective of primary sites or molecular markers, indicated a poor survival prognosis and predicted shorter PFS during bevacizumab treatment in patients with CRC. Further studies are warranted to elucidate the value of c–MET-targeted therapy in CRC patients.  相似文献   
37.
38.
An increasing number of patients are diagnosed with esophageal cancer at an advanced stages, and only a small group of them can benefit from the traditional chemotherapy and radiotherapy. So far, multiple monoclonal antibodies and tyrosine kinase inhibitors have been developed, alone or in combination with traditional therapy, to improve the prognosis of patients with advanced esophageal cancer. This review summarizes the recent advances of targeted therapies against EGFR, HER2, VEGFR and c-MET in esophageal cancer. More clinical trials should be performed to evaluate the efficacy and safety of various targeted therapy regimens. Future basic research should focus on investigating the molecular mechanisms of therapeutic targets in esophageal cancer.  相似文献   
39.
40.
目的 探究白头翁皂苷D (PSD)对胶质瘤细胞U251MG转移和凋亡的影响及可能机制。方法 采用CCK-8试剂盒检测正常星形胶质细胞和U251MG细胞活力;选用0.0、1.0、2.0及5.0 μmol/L PSD处理U251MG,将细胞分为4组:PSD 0.0 μmol/L组、PSD 1.0 μmol/L组、PSD 2.0 μmol/L组和PSD 5.0 μmol/L组。划痕实验检测细胞迁移能力;Transwell检测细胞侵袭能力;Hoechst 33258染色检测细胞凋亡状况;RT-PCR检测mRNA表达水平;蛋白免疫印迹检测基质金属蛋白酶-2(MMP-2)、尿激酶型纤溶酶原激活物(uPA)、纤溶酶原激活物抑制剂-1(PAI-1)、血管内皮生长因子(VEGF)、cleaved caspase-3、cleaved caspase-9、肝细胞生长因子受体(c-MET)蛋白表达水平。结果 PSD抑制正常星形胶质细胞和胶质瘤细胞U251MG细胞活力。与PSD 0.0 μmol/L组相比较,PSD 1.0、2.0及5.0 μmol/L组细胞迁移率降低(P<0.01),MMP-2、uPA、PAI-1、VEGF、c-MET蛋白水平降低(P<0.05),PSD 1.0 μmol/L组细胞侵袭数降低(P<0.05),PSD 2.0及5.0 μmol/L组细胞侵袭数降低(P<0.01),细胞凋亡率升高(P<0.05),cleaved caspase-3、cleaved caspase-9蛋白水平升高(P<0.05)。结论 PSD通过靶向c-MET抑制胶质瘤细胞U251MG迁移和侵袭,并诱导细胞凋亡。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号